COMPANY DOES NOT PROVIDE EXPANDED ACCESS

Immunomic Therapeutics, Inc. is committed to developing promising new therapies to address unmet medical needs of patients suffering from rare disease.

The company is currently enrolling a phase 1 study evaluating ITI-3000, a plasmid DNA (pDNA) vaccine targeting patients with Merkel cell carcinoma (MCC), a rare but aggressive form of skin cancer that is typically caused by the Merkel cell polyomavirus (MCPyV).

Our goal is to provide access to our vaccine therapy at the appropriate time and in a manner that is most beneficial to the relevant patient population. We believe enrollment in our ongoing clinical trial is the safest and most effective way of achieving this goal.

We do recognize that some patients will not be eligible for our clinical trial and may wish to access our products through expanded access. However, at this time, we do not have the resources available to offer expanded access use of our investigational therapy.

We encourage all patients and physicians who are interested in accessing our ITI-3000 program for Merkel cell carcinoma to visit ClinicalTrials.gov and use Identifier: NCT0542278 to inquire about enrolling.

Immunomic Therapeutics, Inc. may revise this expanded access policy at any time. Additionally, the posting of this policy by Immunomic Therapeutics, Inc. does not serve as a guarantee of access to any specific investigational new drug by any individual patient.

If you have any questions, please reach out to us at info@immunomix.com.